Amyloid Beta Deposition & Degradation

Amyloid beta is a peptide that is a major component of plaques in Alzheimer’s disease (AD). Accumulation induces neurotoxic effects including oxidative damage and mitochondrial dysfunction. Amyliod plaques are being studied as a drug target in the treatment of AD. Here is the latest research on amyloid beta deposition and degradation.

October 16, 2021

Artemether Attenuates Aβ25-35-Induced Cognitive Impairments by Downregulating Aβ, BACE1, mTOR and Tau Proteins.

Clinical Laboratory
Hong-Juan LiChuanhai Cao
October 13, 2021

Microglia-specific ApoE knock-out does not alter Alzheimer's disease plaque pathogenesis or gene expression.

Caden M HenningfieldKim N. Green
October 13, 2021

Effects of estradiol supplementation on the brain transcriptome of old rhesus macaques maintained on an obesogenic diet.

Rita Cervera-JuanesHenryk F Urbanski
October 13, 2021
Open Access

Transmission of amyloid-beta and tau pathologies is associated with cognitive impairments in a primate.

Acta Neuropathologica Communications
Suzanne LamMarc Dhenain
October 13, 2021
Open Access

An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure.

International Journal of Molecular Sciences
Subramanian BoopathiRamón Garduño-Juárez
October 13, 2021
Open Access

Cofilin Signaling in the CNS Physiology and Neurodegeneration.

International Journal of Molecular Sciences
Jannatun Nayem NammeHirohide Takebayashi
October 13, 2021

Isoorientin Affects Markers of Alzheimer's Disease via Effects on the Oral and Gut Microbiota in APP/PS1 Mice.

The Journal of Nutrition
Zhongbao ZhangZhongyi Wu
October 9, 2021

Isolation and Characterization of Heparan Sulfate Containing Amyloid Precursor Protein Degradation Products.

Methods in Molecular Biology
Katrin Mani
October 8, 2021

Neuroprotective Effect of Danggui Shaoyao San via the Mitophagy-Apoptosis Pathway in a Rat Model of Alzheimer's Disease.

Evidence-based Complementary and Alternative Medicine : ECAM
Zhenyan SongShaowu Cheng
October 7, 2021

Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals.

Brain Communications
Silvia IngalaAnouk den Braber
October 7, 2021

Effects and mechanisms of natural products on Alzheimer's disease.

Critical Reviews in Food Science and Nutrition
Zhijun YangHui-Lian Zhu
October 5, 2021

Mechanistic role of boswellic acids in Alzheimer's disease: Emphasis on anti-inflammatory properties.

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Aisha SiddiquiYatinesh Kumari
October 4, 2021

Chitosan-coated Selenium nanoparticles enhance the efficiency of stem cells in the neuroprotection of streptozotocin-induced neurotoxicity in male rats.

The International Journal of Biochemistry & Cell Biology
Sara Soleimani AslSiamak Shahidi
October 3, 2021

Distinct conformers of amyloid beta accumulate in the neocortex of patients with rapidly progressive Alzheimer's disease.

The Journal of Biological Chemistry
He LiuJiri G Safar
October 2, 2021
Open Access

Systematic phenotyping and characterization of the 3xTg-AD mouse model of Alzheimer's Disease

BioRxiv : the Preprint Server for Biology
D. I. JavonilloF. M. LaFerla
October 2, 2021

Preclinical validation of a novel oral Edaravone formulation for treatment of frontotemporal dementia.

Neurotoxicity Research
Sally KellinyXin-Fu Zhou

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved